Allergan PLC. (AGN) Shares Sold by Brown Brothers Harriman & Co.
Brown Brothers Harriman & Co. decreased its stake in Allergan PLC. (NYSE:AGN) by 33.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,655 shares of the company’s stock after selling 3,764 shares during the period. Brown Brothers Harriman & Co.’s holdings in Allergan PLC. were worth $1,763,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Miller Howard Investments Inc. NY acquired a new stake in Allergan PLC. during the second quarter worth approximately $1,771,000. Parkwood LLC increased its stake in Allergan PLC. by 55.0% in the second quarter. Parkwood LLC now owns 14,536 shares of the company’s stock worth $3,359,000 after buying an additional 5,159 shares during the last quarter. Highstreet Asset Management Inc. acquired a new stake in Allergan PLC. during the second quarter worth approximately $1,358,000. YHB Investment Advisors Inc. increased its stake in Allergan PLC. by 0.4% in the second quarter. YHB Investment Advisors Inc. now owns 4,899 shares of the company’s stock worth $1,132,000 after buying an additional 18 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its stake in Allergan PLC. by 141.7% in the second quarter. Robeco Institutional Asset Management B.V. now owns 72,893 shares of the company’s stock worth $16,844,000 after buying an additional 42,730 shares during the last quarter. Hedge funds and other institutional investors own 86.72% of the company’s stock.
Allergan PLC. (NYSE:AGN) traded down 0.05% on Friday, reaching $216.14. 3,869,694 shares of the company’s stock were exchanged. The firm has a market capitalization of $81.07 billion, a price-to-earnings ratio of 6.06 and a beta of 1.02. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $301.98. The stock’s 50 day moving average price is $200.06 and its 200 day moving average price is $225.49.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $3.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.65 by $0.33. Allergan PLC. had a net margin of 93.74% and a return on equity of 7.26%. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.73 billion. During the same quarter last year, the business posted $3.48 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, analysts expect that Allergan PLC. will post $13.39 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Stockholders of record on Tuesday, February 28th will be given a dividend of $0.70 per share. This is a positive change from Allergan PLC.’s previous quarterly dividend of $0.05. The ex-dividend date is Friday, February 24th. This represents a $2.80 annualized dividend and a dividend yield of 1.30%.
COPYRIGHT VIOLATION NOTICE: This article was originally reported by Daily Political and is the propert of of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this article can be accessed at http://www.dailypolitical.com/2017/01/13/allergan-plc-agn-shares-sold-by-brown-brothers-harriman-co.html.
A number of analysts have commented on AGN shares. Bank of America set a $294.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a report on Tuesday, September 20th. Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “conviction-buy” rating to a “buy” rating in a report on Wednesday, December 21st. Deutsche Bank AG reiterated a “buy” rating and issued a $247.00 price objective (up previously from $245.00) on shares of Allergan PLC. in a report on Friday, December 23rd. J P Morgan Chase & Co set a $300.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a report on Monday, December 5th. Finally, RBC Capital Markets restated an “outperform” rating and set a $279.00 price target (down previously from $300.00) on shares of Allergan PLC. in a report on Thursday, November 3rd. Eight investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. Allergan PLC. presently has a consensus rating of “Buy” and a consensus target price of $273.10.
In other Allergan PLC. news, Director Nesli Basgoz sold 500 shares of the firm’s stock in a transaction dated Thursday, December 8th. The shares were sold at an average price of $188.72, for a total value of $94,360.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Maria Teresa Hilado bought 1,422 shares of the firm’s stock in a transaction on Friday, November 11th. The stock was purchased at an average price of $210.64 per share, with a total value of $299,530.08. Following the completion of the acquisition, the chief financial officer now owns 12,659 shares of the company’s stock, valued at $2,666,491.76. The disclosure for this purchase can be found here. Insiders own 0.27% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.